JP2002029998A5 - - Google Patents

Download PDF

Info

Publication number
JP2002029998A5
JP2002029998A5 JP2000212576A JP2000212576A JP2002029998A5 JP 2002029998 A5 JP2002029998 A5 JP 2002029998A5 JP 2000212576 A JP2000212576 A JP 2000212576A JP 2000212576 A JP2000212576 A JP 2000212576A JP 2002029998 A5 JP2002029998 A5 JP 2002029998A5
Authority
JP
Japan
Prior art keywords
canine
rheumatoid arthritis
interferon
therapeutic agent
pannus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000212576A
Other languages
Japanese (ja)
Other versions
JP2002029998A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2000212576A priority Critical patent/JP2002029998A/en
Priority claimed from JP2000212576A external-priority patent/JP2002029998A/en
Publication of JP2002029998A publication Critical patent/JP2002029998A/en
Publication of JP2002029998A5 publication Critical patent/JP2002029998A5/ja
Pending legal-status Critical Current

Links

Description

【０００８】
インターフェロンはイヌのパンヌスに注射投与される。パンヌスの存在は公知の方法に従ってＭＲＩで確認することができる。[0008]
Interferon is administered by injection to dogs Pa N'nusu. The presence of Pa N'nusu can be confirmed by MRI according to known methods.

Claims (6)

インターフェロンを有効成分として含むイヌの関節リウマチ治療剤。A therapeutic agent for canine rheumatoid arthritis, which comprises interferon as an active ingredient. インターフェロンがイヌインターフェロン−γである請求項１に記載の治療剤。The therapeutic agent according to claim 1, wherein the interferon is canine interferon - γ. 関節リウマチのイヌのパンヌスに請求項１または２に記載の治療剤を注射投与することを特徴とするイヌの関節リウマチ治療方法。A method for treating rheumatoid arthritis in a canine, comprising administering the therapeutic agent according to claim 1 or 2 by injection to pannus in a canine rheumatoid arthritis. 投与量がイヌ体重あたり０． ５〜２． ５万単位／ｋｇである請求項３に記載の治療方法。The dose is 0. 0 per dog weight. 5-2. The treatment method according to claim 3, which is 50,000 units / kg. １日１回以上、連続して４日以上投与する請求項３または４に記載の治療方法。The method according to claim 3 or 4, wherein the agent is administered once or more daily, continuously for 4 days or more. パンヌスの存在をＭＲＩで確認する請求項３〜５のいずれかに記載の治療方法。The treatment method according to any one of claims 3 to 5, wherein the presence of pannus is confirmed by MRI.
JP2000212576A 2000-07-13 2000-07-13 Therapeutic agent for canine rheumatoid arthritis and therapy therefor Pending JP2002029998A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2000212576A JP2002029998A (en) 2000-07-13 2000-07-13 Therapeutic agent for canine rheumatoid arthritis and therapy therefor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000212576A JP2002029998A (en) 2000-07-13 2000-07-13 Therapeutic agent for canine rheumatoid arthritis and therapy therefor

Publications (2)

Publication Number Publication Date
JP2002029998A JP2002029998A (en) 2002-01-29
JP2002029998A5 true JP2002029998A5 (en) 2004-07-22

Family

ID=18708484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000212576A Pending JP2002029998A (en) 2000-07-13 2000-07-13 Therapeutic agent for canine rheumatoid arthritis and therapy therefor

Country Status (1)

Country Link
JP (1) JP2002029998A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003033331A (en) * 2001-07-24 2003-02-04 Univ Nihon Method for diagnosis of early-phase rheumatoid arthritis of animal and method for surgical treatment therefor
JP4523762B2 (en) * 2003-06-11 2010-08-11 学校法人日本大学 Method for inhibiting mass formation

Similar Documents

Publication Publication Date Title
JP2005520778A5 (en)
DE69634609D1 (en) ANALYTIC SYNERGY BY SIMULTANEOUS ADMINISTRATION OF SUBAN-OIL CANS OF A MU-OPIOIDANAGONIST AND A KAPPA-2-OPIOIDANAGONIST
DE60316779D1 (en) THIADIAZOLYLPIPERAZINE DERIVATIVES SUITABLE FOR THE TREATMENT OF BZW. PREVENTION OF PAIN
BRPI0108977B8 (en) azacyclic compounds, pharmaceutical composition and use of a compound or pharmaceutically acceptable salt thereof
JP2003506416A5 (en)
WO2005056524A3 (en) Therapeutic agents useful for treating pain
JP2625457B2 (en) Drugs to prevent or reduce nausea or vomiting
JP2004537500A5 (en)
RU2004135563A (en) MEDICINE FOR TREATING AN INCREASED ACTIVITY OF THE BLADDER
JP2005522527A5 (en)
JP2002523437A5 (en)
JP2002029998A5 (en)
JP2002537246A5 (en)
CO5221063A1 (en) TOPICAL TREATMENT FOR ANIMAL INSECT PESTS
Schmidt Antagonism of xylazine sedation by yohimbine and 4-aminopyridine in an adult Asian elephant (Elephas maximus)
RU99123225A (en) METHOD FOR TREATING SEVERE BRONCH-OBSTRUCTIVE SYNDROME IN CHILDREN OF EARLY AGE
RU2003118131A (en) METHOD FOR TREATING RAS
RU2003110967A (en) METHOD OF APPLICATION OF ETHIDIUM BROMISTOUS FOR TREATMENT OF HYPROPLASMOSIS
RU2003123827A (en) METHOD FOR COMBINED TREATMENT OF ANIMAL STRONGILYTOSIS
RU2002104662A (en) Method for the prevention of postpartum endometritis in cows
RU2001113054A (en) A method for the treatment of postpartum acute purulent-catarrhal endometritis of cows
RU2003125149A (en) THE DRUG FOR THE TREATMENT OF HEMOBARTONELLOSIS OF CATS AND THE METHOD OF ITS APPLICATION
RU2008152690A (en) METHOD FOR TREATING ANIMALS IN POST-PERMANENT ENDOMETRITIS
RU2002108806A (en) A method for the treatment of autoimmune arthritis in animals
EA200600801A1 (en) MICROSPHERES OF TWO ANTITUBERCULOSIS PREPARATIONS AND BIO-LAYING POLYMER, INTRODUCED BY INHALATION ONLY OR IN COMBINATION WITH INTAKE, AND METHOD OF THEIR RECEPTION